Long-term effects of weight-reducing drugs in hypertensive patients.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2009-07-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD007654.pub3PMID 23543553
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

  2012cited by this paper
• Does rimonabant independently affect free fatty acid and glucose metabolism?

  2012cited by this paper
• Interventions for latent autoimmune diabetes (LADA) in adults.

  2011cited by this paper
• Evaluation of efficacy and safety of orlistat in obese patients

  2011cited by this paper
• Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients

  2011cited by this paper
• Effect of rimonabant on carotid intima–media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial

  2011cited by this paper
• Metabolic Syndrome and Changes in Body Fat From a Low‐fat Diet and/or Exercise Randomized Controlled Trial

  2010cited by this paper
• Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.

  2010cited by this paper
• Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment—Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial

  2010cited by this paper
• Caloric restriction with or without exercise: the fitness versus fatness debate.

  2010cited by this paper
• Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

  2010cited by this paper
• Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

  2010cited by this paper
• The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

  2010cited by this paper
• EFFECTS ON MORTALITY AND MORBIDITY IN OVERWEIGHT/OBESE SUBJECTS: THE SIBUTRAMINE CARDIOVASCULAR OUTCOMES (SCOUT) TRIAL

  2010cited by this paper
• Blood pressure changes associated with sibutramine and weight management – an analysis from the 6‐week lead‐in period of the sibutramine cardiovascular outcomes trial (SCOUT) *

  2009cited by this paper
• A significant decrease in blood pressure through a family-based nutrition health education programme among community residents in Taiwan

  2009cited by this paper
• Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.

  2009cited by this paper
• Estudo Comparativo, Aleatorizado, em Dupla Ocultação, de Orlistat Versus Placebo, de Eficácia e Segurança, em Doentes Obesos com Hipercolesterolemia Ligeira a Moderada

  2009cited by this paper
• Reduction in consumption of sugar-sweetened beverages is associated with weight loss: the PREMIER trial.

  2009cited by this paper
• Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea.

  2009cited by this paper
• Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome.

  2009cited by this paper
• Long-term effects of weight-reducing drugs in hypertensive patients.

  2009cited by this paper
• Association of 1-y changes in diet pattern with cardiovascular disease risk factors and adipokines: results from the 1-y randomized Oslo Diet and Exercise Study.

  2009cited by this paper
• Obesity-related hypertension.

  2009cited by this paper
• Treatment of hypertension in obese patients: efficacy and feasibility of weight and salt reduction programs.

  2009cited by this paper
• Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients: Systematic Review and Meta-analysis

  2009cited by this paper
• Factors Affecting Blood Pressure Variability: Lessons Learned from Two Systematic Reviews of Randomized Controlled Trials

  2009cited by this paper
• Effect of Rimonabant on the High-Triglyceride/Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat: The ADAGIO-Lipids Trial

  2009cited by this paper
• A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial

  2008cited by this paper
• Downregulation of genes involved in NFκB activation in peripheral blood mononuclear cells after weight loss is associated with the improvement of insulin sensitivity in individuals with the metabolic syndrome: the GENOBIN study

  2008cited by this paper
• Triacylglycerol Fatty Acid Composition in Diet-Induced Weight Loss in Subjects with Abnormal Glucose Metabolism – the GENOBIN Study

  2008cited by this paper
• Effect of Orlistat on Eating Behavior Among Participants in a 3‐year Weight Maintenance Trial

  2008cited by this paper
• PERSONALITY TRAITS AS PREDICTORS OF CARDIAC REHABILITATION PARTICIPATION

  2008cited by this paper
• Weight reduction modulates expression of genes involved in extracellular matrix and cell death: the GENOBIN study

  2008cited by this paper
• Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

  2008cited by this paper
• Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis.

  2008cited by this paper
• Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial.

  2008cited by this paper
• Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

  2008cited by this paper
• Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

  2008cited by this paper
• Low-Fat Dietary Pattern and Risk of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial

  2007cited by this paper
• Never too old for statins

  2007cited by this paper
• Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

  2007cited by this paper
• Placebo

  2007cited by this paper
• Long term pharmacotherapy for obesity and overweight: updated meta-analysis

  2007cited by this paper
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

  2007cited by this paper
• Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

  2007cited by this paper
• overweight: updated meta-analysis Long term pharmacotherapy for obesity and

  2007cited by this paper
• Randomized Controlled Trial on Lifestyle Modification in Hypertensive Patients

  2006cited by this paper
• Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

  2006cited by this paper
• Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

  2006cited by this paper
• Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials

  2006cited by this paper
• Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003–2004 Secondary Prevention Trials

  2005cited by this paper
• Efficacia e sicurezza di impiego di un trattamento a breve termine con orlistat in soggetti obesi

  2005cited by this paper
• Effect of orlistat on cardiovascular disease risk in obese adults

  2005cited by this paper
• Diet and blood pressure: applying the evidence to clinical practice.

  2005cited by this paper
• Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

  2005cited by this paper
• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

  2005cited by this paper
• Effects of Weight Loss in Overweight/Obese Individuals and Long-Term Hypertension Outcomes: A Systematic Review

  2005cited by this paper
• Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes

  2005cited by this paper
• Sufficient Weight Reduction Decreases Cardiovascular Complications in Diabetic Patients with the Metabolic Syndrome

  2005cited by this paper
• Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients

  2005cited by this paper
• Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region.

  2005cited by this paper
• The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients

  2005cited by this paper
• Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

  2005cited by this paper
• Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.

  2004cited by this paper
• Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization

  2004cited by this paper
• Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience.

  2004cited by this paper
• Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women.

  2004cited by this paper
• Cholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations

  2004cited by this paper
• XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

  2004cited by this paper
• Effects of orlistat on obesity‐related diseases – a six‐month randomized trial

  2004cited by this paper
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

  2004cited by this paper
• Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes

  2004cited by this paper
• Low-fat diet: effect on anthropometrics, blood pressure, glucose, and insulin in older women.

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.

  2003cited by this paper
• Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension

  2003cited by this paper
• Advice from primary-care physicians and nurses may improve diet in people with hypertension

  2003cited by this paper
• The world health report 2002 - reducing risks, promoting healthy life.

  2003cited by this paper
• A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.

  2003cited by this paper
• Latin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients

  2003cited by this paper
• A low-carbohydrate as compared with a low-fat diet in severe obesity.

  2003cited by this paper
• Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

  2003cited by this paper
• Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.

  2003cited by this paper
• Decreasing levels of tumour necrosis factor α and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors

  2003cited by this paper
• Advice or exercise for chronic whiplash disorders? Design of a randomized controlled trial

  2003cited by this paper
• Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double‐blind, randomized, placebo‐controlled trial

  2003cited by this paper
• Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

  2002cited by this paper
• Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.

  2002cited by this paper
• Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

  2002cited by this paper
• Erratum: Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin (Diabetes Care (2002) 25 (1123-1128))

  2002cited by this paper
• Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

  2002cited by this paper
• Persistence of normotension after discontinuation of lifestyle intervention in the trial of TONE. Trial of Nonpharmacologic Interventions in the Elderly.

  2002cited by this paper
• Ethnic comparison of weight loss in the Trial of Nonpharmacologic Interventions in the Elderly.

  2002cited by this paper
• New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.

  2002cited by this paper
• Effects of sibutramine on the treatment of obesity in patients with arterial hypertension.

  2002cited by this paper
• Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.

  2002cited by this paper
• Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

  2002cited by this paper

• Influence of Obesity on Blood Pressure Responses to Antihypertensive Drug Therapy in an Urban Hypertension Specialty Clinic.

  2022cites this paper
• The Fatty Acid Lipid Metabolism Nexus in COVID-19

  2021cites this paper
• Long-term effects of weight-reducing drugs in people with hypertension.

  2021cites this paper
• Effect of Two Meal Replacement strategies on Cardiovascular Risk Parameters in Advanced Age Patients with Obesity and Osteoarthritis

  2020cites this paper
• Body mass index and heart failure risk: a cohort study in 1.5 million individuals and Mendelian randomisation analysis

  2020cites this paper
• Association of demographic and socioeconomic characteristics with body mass index of outpatient diabetic adults attending a tertiary health facility in Enugu, Nigeria.

  2019cites this paper
• Human Enhancement Drugs

  2019cites this paper
• Decreases in adiposity reduce the risk of hypertension: Results from a prospective cohort of adolescents.

  2019cites this paper
• Anti-Inflammatory Effects of Melatonin in Obesity and Hypertension

  2018cites this paper
• The Association Between Obesity and Visit-to-Visit Variability in Systolic Blood Pressure: A Prospective Study

  2017cites this paper
• The role of bariatric surgery for improvement of hypertension in obese patients: a retrospective study

  2017cites this paper
• Epidemiology of Obesity and Pharmacologic Treatment Options

  2017cites this paper
• Glucagon-like peptide-1 agonists for weight loss in people with obesity

  2017cites this paper
• Metabolic syndrome is associated with increased risk of short-term post-procedural complications after carotid artery stenting

  2017cites this paper
• The effects of body weight loss and gain on arterial hypertension control: an observational prospective study

  2017cites this paper
• Applying for, reviewing and funding public health research in Germany and beyond

  2016cites this paper
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.

  2016cites this paper
• Intentional Weight Loss and Longevity in Overweight Patients with Type 2 Diabetes: A Population-Based Cohort Study

  2016cites this paper
• Long-term effects of weight-reducing drugs in people with hypertension.

  2016cites this paper
• The Effect of Theory Based Nutritional Education on Fat Intake, Weight and Blood Lipids

  2016cites this paper
• The Saudi clinical practice guideline for the management of overweight and obesity in adults

  2016cites this paper
• Long-term effects of weight-reducing diets in people with hypertension.

  2016cites this paper
• Calorie restriction mimetics: can you have your cake and eat it, too?

  2015cites this paper
• Common questions about the initial management of hypertension.

  2015cites this paper
• Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized controlled trials

  2015cites this paper
• Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study.

  2015cites this paper
• Obesity Is Associated with Race/Sex Disparities in Diabetes and Hypertension Prevalence, But Not Cardiovascular Disease, Among HIV-Infected Adults

  2015cites this paper
• Lost in translation: dietary management of cardiovascular risk factors is seldom implemented.

  2015cites this paper
• Anti-hypertensive Drug Treatment of Patients with and the Metabolic Syndrome and Obesity: a Review of Evidence, Meta-Analysis, Post hoc and Guidelines Publications

  2015cites this paper
• Altered dietary salt intake for people with chronic kidney disease.

  2015cites this paper
• An assessment of randomized controlled trials (RCTs) for non-communicable diseases (NCDs): more and higher quality research is required in less developed countries

  2015cites this paper
• ChemDIS: a chemical–disease inference system based on chemical–protein interactions

  2015cites this paper
• Age- and Sex-Specific Causal Effects of Adiposity on Cardiovascular Risk Factors

  2015cites this paper
• The Effects of a Diet and Exercise Program for Older Adults With Metabolic Syndrome

  2015cites this paper
• Anti-adipogenic effect of Artemisia annua in diet-induced-obesity mice model

  2015cites this paper
• The anti-obesity drug orlistat reveals anti-viral activity

  2015cites this paper
• Health Benefits of Long-Term Weight-Loss Maintenance.

  2015cites this paper
• Weight loss is a useful therapeutic objective.

  2015influential citation
• Pathogenesis of obstructive sleep apnoea in hypertensive patients: role of fluid retention and nocturnal rostral fluid shift

  2014cites this paper
• Codonopsis lanceolata Extract Prevents Diet-Induced Obesity in C57BL/6 Mice

  2014cites this paper
• Investigation of Fat Metabolism during Antiobesity Interventions by Magnetic Resonance Imaging and Spectroscopy

  2014cites this paper
• Should Patients with Obesity and Hypertension be Treated Differently from Those Who Are Not Obese?

  2014cites this paper
• Exercise and Dietary Influences on Arterial Stiffness in Cardiometabolic Disease

  2014cites this paper
• Effects of gastric bypass surgery in patients with hypertension: rationale and design for a randomised controlled trial (GATEWAY study)

  2014cites this paper
• Impact of the Healthy Eating and Exercise Lifestyle Programme on depressive symptoms in overweight people with heart disease and diabetes

  2014cites this paper
• Benefit-Risk Assessment of Orlistat in the Treatment of Obesity

  2014cites this paper
• Obesity: Pathophysiology and Intervention

  2014cites this paper
• Hypertensive Heart Disease and Obesity: A Complex Interaction Between Hemodynamic and Not Hemodynamic Factors

  2014cites this paper
• Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids.

  2014cites this paper
• Prevalence of Hypertension in Hail Region, KSA: in a Comprehensive Survey

  2014cites this paper
• Evaluation of the relationship between Body Mass Index (BMI) and healthcare cost, utilization and health-related quality of life in adult diabetic patients

  2014cites this paper
• Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis.

  2014cites this paper
• 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

  2013cites this paper
• The prodromal phase of obesity-related chronic kidney disease: early alterations in cardiovascular and renal function in obese children and adolescents.

  2013cites this paper
• A low-carbohydrate/high-fat diet reduces blood pressure in spontaneously hypertensive rats without deleterious changes in insulin resistance.

  2013cites this paper
• Hypertension in the elderly: how to treat patients in 2013? The essential recommendations of the Polish guidelines.

  2013cites this paper
• Long-term Effects of Dieting: Is Weight Loss Related to Health?

  2013cites this paper
• Dietary approach to hypertension based on low glycaemic index and principles of DASH (Dietary Approaches to Stop Hypertension): a randomised trial in a primary care service.

  2013cites this paper
• New advances in models and strategies for developing anti-obesity drugs

  2013cites this paper
• Obesity‐related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension

  2013cites this paper
• Update in cardiology: vascular risk and cardiac rehabilitation.

  2013cites this paper
• Practice Guidelines and The Obesity Society Report of the American College of Cardiology/American Heart Association Task Force on 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A

  2013cites this paper
• Safety and effectiveness of LAP-BAND AP System: results of Helping Evaluate Reduction in Obesity (HERO) prospective registry study at 1 year.

  2013cites this paper
• The long-term coronary heart disease risk of previously obese patients with type 2 diabetes mellitus

  2013cites this paper
• Lifestyle Interventions for Patients With and at Risk for Type 2 Diabetes

  2013cites this paper
• A Randomised Trial of a Weight Loss Intervention for Overweight and Obese People Diagnosed with Coronary Heart Disease and/or Type 2 Diabetes

  2012cites this paper
• Neuropeptide Y Promoter Polymorphism Modifies Effects of a Weight-Loss Diet on 2-Year Changes of Blood Pressure: The Preventing Overweight Using Novel Dietary Strategies Trial

  2012cites this paper
• Safety and Efficacy of the LAP-BAND AP® Adjustable Gastric Band in the Treatment of Obesity: Results at 2 Years

  2012cites this paper
• The obesity epidemic and its impact on hypertension.

  2012cites this paper
• Recomendaciones preventivas cardiovasculares

  2012cites this paper
• Drug Treatment for Obesity in the Post-Sibutramine Era

  2011cites this paper